



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/801,059

03/16/2004

Mark Gelfand

3659-87

1197

23117

7590

08/29/2006

NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON, VA 22203

EXAMINER

DEAK, LESLIE R

ART UNIT

PAPER NUMBER

3761

DATE MAILED: 08/29/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/801,059	GELFAND ET AL.	
	Examiner	Art Unit	
	Leslie R. Deak	3761	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 June 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 19-25 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 19-25 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 16 March 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claims 19-25 are rejected under 35 U.S.C. 102(e) as being anticipated by US 6,471,872 to Kitaevich et al.

Kitaevich discloses, in the specification and figures, the device as claimed by applicant. In particular, Kitaevich discloses a renal function replacement apparatus which may perform hemofiltration, hemodialysis, or ultrafiltration (see column 2, lines 45-63). The system further comprises a blood withdrawal tube 14, blood reinfusion tube 30, filter 24, filtrate output section 64 and pump 66, a biosensor 140, and a controller 12 (see column 6, generally, column 7, lines 21-35, column 9, lines 16-25). The apparatus monitors patient parameters that may include patient cardiac output, or oxygen saturation in the blood, and that signal is compared to upper and lower values (which are considered to correspond to applicant's threshold and baseline values) and used to control the fluid pumping rates (increasing or decreasing the pumping rate) in the system (see column 3, lines 50-55, column 4, lines 28-37, column 8, lines 32-45). Kitaevich further discloses that the controller may be used in an automatic mode wherein one or more patient parameters are monitored during the hemofiltration operation (which includes an initial phase of blood filtration treatment as claimed by

Art Unit: 3761

applicant). The controller then operates based on this real-time patient data, considering one or more specific parameters that are stored, at least briefly, in the controller's processor in order to automatically adjust the operation of the blood filtration device (see column 4, lines 37-43).

With regard to the step of storing a baseline feedback signal during an initial phase of blood filtration treatment, Kitaevich specifically discloses that patient parameters may be programmed into the controller at the start of the blood treatment procedure (see column 9, lines 16-35). Such programming is within the scope of applicant's claimed "initial phase" of blood filtration treatment, since setting up the machine and controller are part of the blood treatment procedure, and such programming may be called an "initial phase" of blood treatment.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claim 21 is rejected under 35 U.S.C. 103(a) as being unpatentable over US 6,417,872 to Kitaevich et al as applied above, in view of US 4,739,492 to Cochran.

Kitaevich discloses, in the specification and figures, the device as claimed by applicant, with the exception of using a summation step to determine a feedback signal threshold. However, Cochran discloses a method of providing feedback control to a

Art Unit: 3761

dialysis system comprising the step of adding an delivery temperature error value (based on a predetermined value) to a temperature obtained via feedback signal. The final delivery temperature error is used as a threshold to toggle the heater on and off during treatment (see column 10, lines 15-57). Cochran discloses that the procedure allows for improved parameter monitoring by comparing actual operating parameters to estimated operating parameters in order to provide more accurate blood treatment (see column 3, lines 15-20).

Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to use the summation step disclosed by Cochran in the control algorithm disclosed by Kitaevich in order to provide for more accurate feedback control of the blood treatment system, as taught by Cochran.

Response to Arguments

5. Applicant's amendment and arguments filed 28 June 2006 have been entered and fully considered but they are not persuasive.

6. Applicant argues that the Kitaevich device does not perform the steps claimed by applicant. However, applicant's recitations, as presented, drawn to the controller, do not positively claim the actions of the controller. It has been held that a recitation with respect to the manner in which a claimed apparatus is intended to be employed does not differentiate the claimed apparatus from a prior art apparatus satisfying the claimed structural limitations. See MPEP 2114. In the instant case, Kitaevich discloses the structural limitations of the device as claimed by applicant, and controller that is capable

of performing the actions argued by applicant. As such, the Kitaevich device meets the limitations of the claims.

Examiner recommends that applicant recite the functions of the controller in a manner that claims that the controller is "programmed to" perform the argued functions.

Conclusion

7. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leslie R. Deak whose telephone number is 571-272-4943. The examiner can normally be reached on M-F 7:30-5:00, every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tanya Zalukaeva can be reached on 571-272-1115. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3761

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Leslie R. Deak
Patent Examiner
Art Unit 3761
22 August 2006

TATYANA ZALUKAEVA
SUPERVISORY PRIMARY EXAMINER

